Since tumor adaptive resistance to genotoxic stress was attributed to BCL6 transactivation, we tested whether pharmacological inhibition of BCL6 could restore the sensitivity of resistant cancer cells to genotoxic agents. Here, BCL6 is linked to neoplasm.